[시장보고서]세계의 종양학 동반진단 검사 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

세계의 종양학 동반진단 검사 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1487557

리서치사 : Transparency Market Research

발행일 : 2024년 04월

페이지 정보 : 영문 232 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,449,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,823,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,197,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

종양학 분야 동반진단 검사 시장 - 조사 범위

TMR의 종양학 분야 동반진단 검사 세계 시장 조사 보고서는 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측연도로 하여 2018년부터 2034년까지 세계 종양학 동반진단 검사 시장의 수익과 예측을 제공합니다. 또한, 2024년부터 2034년까지 세계 동반진단검사 시장의 연평균 성장률(CAGR%)을 제시합니다.

이 보고서는 1차적으로 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 인터뷰하고, 2차적으로 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참고하여 종양학 분야의 동반진단 검사 시장을 파악하기 위해 광범위한 조사를 통해 작성되었습니다. 동반진단검사 시장을 파악하기 위해 주요 기업의 제품 자료, 연차보고서, 보도자료, 관련 문서 등을 참고하였습니다.

시장 현황
2023년 시장 규모	61억 달러
2034년 시장 가치	170억 달러
CAGR	9.5%

이 보고서는 종양학 분야의 동반진단검사(Companion Diagnostic Testing in Oncology) 세계 시장 경쟁 구도를 조사했습니다. 종양학 동반 진단 테스트 세계 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에서 프로파일링된 세계 동반 진단 테스트 시장의 기업 속성입니다.

시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
- Abbott
- F. Hoffmann-LA Roche AG
- Genomic Health, Inc.
- QIAGEN
- Agilent Technologies, Inc.
- AGENDIA N.V.
- bioMerieux SA
- Illumina, Inc.
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- BioGenex

LSH

영문 목차

영문목차

Companion Diagnostic Tests in Oncology Market - Scope of Report

TMR's report on the global companion diagnostic tests in oncology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global companion diagnostic tests in oncology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global companion diagnostic tests in oncology market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the companion diagnostic tests in oncology market.

Market Snapshot
Market Value in 2023	US$ 6.1 Bn
Market Value in 2034	US$ 17 Bn
CAGR	9.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global companion diagnostic tests in oncology market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global companion diagnostic tests in oncology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global companion diagnostic tests in oncology market.

The report delves into the competitive landscape of the global companion diagnostic tests in oncology market. Key players operating in the global companion diagnostic tests in oncology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global companion diagnostic tests in oncology market profiled in this report.

Key Questions Answered in Global companion diagnostic tests in oncology Market Report:

What is the sales/revenue generated by companion diagnostic tests in oncology across all regions during the forecast period?
What are the opportunities in the global companion diagnostic tests in oncology market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Companion Diagnostic Tests in Oncology Market - Research Objectives and Research Approach

The comprehensive report on the global companion diagnostic tests in oncology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global companion diagnostic tests in oncology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global companion diagnostic tests in oncology market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
- 6.3.1. Protein Detection
  - 6.3.1.1. Immunohistochemistry
- 6.3.2. DNA Detection
  - 6.3.2.1. Polymerase Chain Reaction (PCR)
  - 6.3.2.2. Next-generation Sequencing (NGS)
  - 6.3.2.3. In Situ Hybridization
- 6.3.3. Others
6.4. Market Attractiveness, by Detection Technique

7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Biomarker, 2020 - 2034
- 7.3.1. EGFR
- 7.3.2. KRAS
- 7.3.3. HER2
- 7.3.4. BRAF V600E
- 7.3.5. Others
- 7.3.6. 7.4 Market Attractiveness, by Biomarker

8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type

8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
- 8.3.1. Breast Cancer
- 8.3.2. Lung Cancer
- 8.3.3. Colorectal Cancer
- 8.3.4. Liver Cancer
- 8.3.5. Melanoma
- 8.3.6. Others
8.4. Market Attractiveness, by Cancer Type

9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user

9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020 - 2034
- 9.3.1. Hospitals
- 9.3.2. Specialty Clinics
- 9.3.3. Diagnostic Labs
- 9.3.4. Others
9.4. Market Attractiveness, by End-user

10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020 - 2034
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 11.2.1. Protein Detection
  - 11.2.1.1. Immunohistochemistry
- 11.2.2. DNA Detection
  - 11.2.2.1. Polymerase Chain Reaction (PCR)
  - 11.2.2.2. Next-generation Sequencing (NGS)
  - 11.2.2.3. In Situ Hybridization
- 11.2.3. Others
11.3. Market Attractiveness, by Detection Technique
11.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 11.4.1. EGFR
- 11.4.2. KRAS
- 11.4.3. HER2
- 11.4.4. BRAF V600E
- 11.4.5. Others
11.5. Market Attractiveness, by Biomarker
11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 11.6.1. Breast Cancer
- 11.6.2. Lung Cancer
- 11.6.3. Colorectal Cancer
- 11.6.4. Liver Cancer
- 11.6.5. Melanoma
- 11.6.6. Others
11.7. Market Attractiveness, by Cancer Type
11.8. Market Value Forecast, by End-user, 2020 - 2034
- 11.8.1. Hospitals
- 11.8.2. Specialty Clinics
- 11.8.3. Diagnostic Labs
- 11.8.4. Others
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country, 2020 - 2034
- 11.10.1. U.S.
- 11.10.2. Canada
11.11. Market Attractiveness Analysis
- 11.11.1. By Detection Technique
- 11.11.2. By Biomarker
- 11.11.3. By Cancer Type
- 11.11.4. By End-user
- 11.11.5. By Country

12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 12.2.1. Protein Detection
  - 12.2.1.1. Immunohistochemistry
- 12.2.2. DNA Detection
  - 12.2.2.1. Polymerase Chain Reaction (PCR)
  - 12.2.2.2. Next-generation Sequencing (NGS)
  - 12.2.2.3. In Situ Hybridization
- 12.2.3. Others
12.3. Market Attractiveness, by Detection Technique
12.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 12.4.1. EGFR
- 12.4.2. KRAS
- 12.4.3. HER2
- 12.4.4. BRAF V600E
- 12.4.5. Others
12.5. Market Attractiveness, by Biomarker
12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 12.6.1. Breast Cancer
- 12.6.2. Lung Cancer
- 12.6.3. Colorectal Cancer
- 12.6.4. Liver Cancer
- 12.6.5. Melanoma
- 12.6.6. Others
12.7. Market Attractiveness, by Cancer Type
12.8. Market Value Forecast, by End-user, 2020 - 2034
- 12.8.1. Hospitals
- 12.8.2. Specialty Clinics
- 12.8.3. Diagnostic Labs
- 12.8.4. Others
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
- 12.11.1. By Detection Technique
- 12.11.2. By Biomarker
- 12.11.3. By Cancer Type
- 12.11.4. By End-user
- 12.11.5. By Country/Sub-region

13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 13.2.1. Protein Detection
  - 13.2.1.1. Immunohistochemistry
- 13.2.2. DNA Detection
  - 13.2.2.1. Polymerase Chain Reaction (PCR)
  - 13.2.2.2. Next-generation Sequencing (NGS)
  - 13.2.2.3. In Situ Hybridization
- 13.2.3. Others
13.3. Market Attractiveness, by Detection Technique
13.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 13.4.1. EGFR
- 13.4.2. KRAS
- 13.4.3. HER2
- 13.4.4. BRAF V600E
- 13.4.5. Others
13.5. Market Attractiveness, by Biomarker
13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 13.6.1. Breast Cancer
- 13.6.2. Lung Cancer
- 13.6.3. Colorectal Cancer
- 13.6.4. Liver Cancer
- 13.6.5. Melanoma
- 13.6.6. Others
13.7. Market Attractiveness, by Cancer Type
13.8. Market Value Forecast, by End-user, 2020 - 2034
- 13.8.1. Hospitals
- 13.8.2. Specialty Clinics
- 13.8.3. Diagnostic Labs
- 13.8.4. Others
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
- 13.11.1. By Detection Technique
- 13.11.2. By Biomarker
- 13.11.3. By Cancer Type
- 13.11.4. By End-user
- 13.11.5. By Country/Sub-region

14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 14.2.1. Protein Detection
  - 14.2.1.1. Immunohistochemistry
- 14.2.2. DNA Detection
  - 14.2.2.1. Polymerase Chain Reaction (PCR)
  - 14.2.2.2. Next-generation Sequencing (NGS)
  - 14.2.2.3. In Situ Hybridization
- 14.2.3. Others
14.3. Market Attractiveness, by Detection Technique
14.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 14.4.1. EGFR
- 14.4.2. KRAS
- 14.4.3. HER2
- 14.4.4. BRAF V600E
- 14.4.5. Others
14.5. Market Attractiveness, by Biomarker
14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 14.6.1. Breast Cancer
- 14.6.2. Lung Cancer
- 14.6.3. Colorectal Cancer
- 14.6.4. Liver Cancer
- 14.6.5. Melanoma
- 14.6.6. Others
14.7. Market Attractiveness, by Cancer Type
14.8. Market Value Forecast, by End-user, 2020 - 2034
- 14.8.1. Hospitals
- 14.8.2. Specialty Clinics
- 14.8.3. Diagnostic Labs
- 14.8.4. Others
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
- 14.11.1. By Detection Technique
- 14.11.2. By Biomarker
- 14.11.3. By Cancer Type
- 14.11.4. By End-user
- 14.11.5. By Country/Sub-region

15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
- 15.2.1. Protein Detection
  - 15.2.1.1. Immunohistochemistry
- 15.2.2. DNA Detection
  - 15.2.2.1. Polymerase Chain Reaction (PCR)
  - 15.2.2.2. Next-generation Sequencing (NGS)
  - 15.2.2.3. In Situ Hybridization
- 15.2.3. Others
15.3. Market Attractiveness, by Detection Technique
15.4. Market Value Forecast, by Biomarker, 2020 - 2034
- 15.4.1. EGFR
- 15.4.2. KRAS
- 15.4.3. HER2
- 15.4.4. BRAF V600E
- 15.4.5. Others
15.5. Market Attractiveness, by Biomarker
15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
- 15.6.1. Breast Cancer
- 15.6.2. Lung Cancer
- 15.6.3. Colorectal Cancer
- 15.6.4. Liver Cancer
- 15.6.5. Melanoma
- 15.6.6. Others
15.7. Market Attractiveness, by Cancer Type
15.8. Market Value Forecast, by End-user, 2020 - 2034
- 15.8.1. Hospitals
- 15.8.2. Specialty Clinics
- 15.8.3. Diagnostic Labs
- 15.8.4. Others
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
- 15.11.1. By Detection Technique
- 15.11.2. By Biomarker
- 15.11.3. By Cancer Type
- 15.11.4. By End-user
- 15.11.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
- 16.3.1. Abbott
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. F. Hoffmann-LA Roche AG
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. Genomic Health, Inc.
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. QIAGEN
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. Agilent Technologies, Inc.
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. AGENDIA N.V.
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. bioMerieux SA
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Illumina, Inc.
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Product Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Siemens Healthineers
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Product Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview
- 16.3.10. Thermo Fisher Scientific Inc.
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Product Portfolio
  - 16.3.10.3. Financial Overview
  - 16.3.10.4. SWOT Analysis
  - 16.3.10.5. Strategic Overview
- 16.3.11. BioGenex
  - 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.11.2. Product Portfolio
  - 16.3.11.3. Financial Overview
  - 16.3.11.4. SWOT Analysis
  - 16.3.11.5. Strategic Overview

한글목차

종양학 분야 동반진단 검사 시장 - 조사 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장 분석과 예측 : 탐지 기술별

제7장 세계 시장 분석과 예측 : 바이오마커별

제8장 세계 시장 분석과 예측 : 암 유형별

제9장 세계 시장 분석과 예측 : 최종사용자별

제10장 세계 시장 분석과 예측 : 지역별

제11장 북미 시장 분석과 예측

제12장 유럽 시장 분석과 예측

제13장 아시아태평양 시장 분석과 예측

제14장 라틴아메리카 시장 분석과 예측

제15장 중동 및 아프리카 시장 분석과 예측

제16장 경쟁 구도